WO2008012283A1 - Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine - Google Patents

Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine Download PDF

Info

Publication number
WO2008012283A1
WO2008012283A1 PCT/EP2007/057559 EP2007057559W WO2008012283A1 WO 2008012283 A1 WO2008012283 A1 WO 2008012283A1 EP 2007057559 W EP2007057559 W EP 2007057559W WO 2008012283 A1 WO2008012283 A1 WO 2008012283A1
Authority
WO
WIPO (PCT)
Prior art keywords
anhydride
methoxyphenyl
process according
compound
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/057559
Other languages
French (fr)
Inventor
Walter Ferdinand Maria Filliers
Rudy Laurent Maria Broeckx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/374,894 priority Critical patent/US8138376B2/en
Priority to MX2009000911A priority patent/MX2009000911A/en
Priority to DE602007004494T priority patent/DE602007004494D1/en
Priority to PL07787803T priority patent/PL2046726T3/en
Priority to HR20100197T priority patent/HRP20100197T1/en
Priority to HK09111685.8A priority patent/HK1134280B/en
Priority to KR1020097000899A priority patent/KR101370398B1/en
Priority to CA2656696A priority patent/CA2656696C/en
Priority to CN2007800284726A priority patent/CN101495447B/en
Priority to AT07787803T priority patent/ATE455752T1/en
Priority to EP07787803A priority patent/EP2046726B1/en
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to JP2009521242A priority patent/JP5208933B2/en
Priority to AU2007278224A priority patent/AU2007278224C1/en
Priority to EA200970147A priority patent/EA015003B1/en
Priority to BRPI0714671A priority patent/BRPI0714671B8/en
Priority to DK07787803.1T priority patent/DK2046726T3/en
Publication of WO2008012283A1 publication Critical patent/WO2008012283A1/en
Priority to IL196627A priority patent/IL196627A/en
Anticipated expiration legal-status Critical
Priority to US13/397,186 priority patent/US8440863B2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups

Definitions

  • the present invention relates to an improved process for the preparation of (2R,3R)-3- (3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.
  • Tapentadol is the INN (International Non-proprietary Name) of 3-[(lR,2R)-3- (dimethylamino)-l-ethyl-2-methylpropyl]phenol monohydrochloride which compound is represented by the formula :
  • the synthetic precursor of tapentadol in the above scheme is (2R,3R)-3-(3-methoxy- phenyl)-N,N,2-trimethylpentanamine (intermediate (+23) in the above scheme) which can be obtained by removing the tertiary hydroxy group of (2 l S r ,3 ⁇ )-l-(dimethylamino)- 3-(3-methoxyphenyl)-2-methyl-3-pentanol by consecutive conversion into the corresponding halogenide with thionyl chloride and subsequent removal of the Cl by treatment with zinc borohydride, zinc cyanoborohydride and/or tin cyanoborohydride.
  • WO-2004/108658 discloses an alternative process for obtaining (2R,3R)-3-(3-methoxy- phenyl)-N,N,2-trimethylpentanamine by converting (2S,3S)-l-(dimethylamino)-3-(3- methoxyphenyl)-2-methyl-3-pentanol into a mixture of (2R,3R) and (2R,3S)-3-(3- methoxyphenyl)-N,N,2-trimethylpentanamine as outlined below.
  • WO-2005/000788 discloses an alternative process for obtaining (2R,3R)-3-(3-methoxy- phenyl)-N,N,2-trimethylpentanamine by converting (2S,3S)-l-(dimethylamino)-3-(3- methoxyphenyl)-2-methyl-3-pentanol into a mixture of (2R,3R) and (2R,3S)-3-(3- methoxyphenyl)-N,N,2-trimethylpentanamine as outlined below.
  • the object of the present invention is to provide an improved method for the synthesis of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine which is more convenient and more efficient than the previously known methods.
  • - A
  • the present invention achieves this object by providing an improved process for the preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine, or an acid addition salt thereof, which is characterized by the steps of a) acylating (2 l S r ,3R)-l-(dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol
  • the acylating agent of step a) is an organic acyl halide or organic acid anhydride selected from acetic anhydride, acetyl chloride, trifluoroacetic anhydride, chloroacetic anhydride, chloro acetylchloride, dichloroacetic anhydride, trichloroacetic anhydride, benzoic anhydride, benzoyl chloride, phthalic anhydride, phtaloyl dichloride, terephthaloyldichloride, succinic anhydride, succinyl chloride, ethyl oxalyl chloride, methyl oxalyl chloride, Meldrum's acid, ethyl chloroformate, methylchloroformate, acetylsalicyloyl chloride, or any other suitable acylating agent.
  • the acylation reaction of step a) may be performed in the presence of a suitable base, such as e.g
  • the catalyst of step b) is selected from a palladium catalyst, or any other suitable catalyst such as e.g. Raney nickel, platinum, platinum on carbon, ruthenium or rhodium on carbon.
  • the palladium (Pd) catalyst may be a homogeneous Pd catalyst, such as for example Pd(OAc) 2 , PdCl 2 , Pd(PPh 3 ) 4 , Pd(PPh 3 ) 2 Cl 2 , Pd 2 (dba) 3 (tris(dibenzylidene acetone) dipalladium), palladium thiomethylphenylglutaramide metallacycle and the like, or a heterogeneous Pd catalyst, such as for example palladium on charcoal, palladium on metal oxides, palladium on zeolites.
  • a homogeneous Pd catalyst such as for example Pd(OAc) 2 , PdCl 2 , Pd(PPh 3 ) 4 , Pd(PPh 3 ) 2 Cl 2 , Pd 2 (dba) 3 (tris(dibenzylidene acetone) dipalladium), palladium thiomethylphenylglutaramide metallacycle
  • the palladium catalyst is a heterogeneous Pd catalyst, more preferably palladium on charcoal or palladium on carbon (Pd/C).
  • Pd/C is a recoverable catalyst, is stable and relatively inexpensive. It can be easily separated (filtration) from the reaction mixture thereby reducing the risk of Pd traces in the final product.
  • the use of Pd/C also avoids the need for ligands, such as for example phosphine ligands, which are expensive, toxic and contaminants of the synthesized products.
  • the reaction-inert solvent of step b) is selected from diethyl ether, tetrahydrofuran, 2-methyltetrahydrofuran or mixtures thereof.
  • steps a) and b) are executed as a "one pot synthesis" procedure.
  • the present invention also relates to novel compounds of formula (III)
  • the acyl group in compounds of formula (III) represents CH3-CO-, CF3-CO-, CH 2 Cl-CO-, CHCl 2 -CO-, CCl 3 -CO-, CH 3 O-CO-CO-, CH 3 O-CO-, CH 3 CH 2 O-CO-, CH 3 CH 2 O-CO-CO, phenyl-CO-, or meta-CH 3 COO-phenyl-CO- when the acylating agent used to prepared the compounds of formula (III) as set out above is selected from acetic anhydride, acetyl chloride, trifluoroacetic anhydride, chloroacetic anhydride, chloro acetylchloride, dichloroacetic anhydride, trichloroacetic anhydride, methyl oxalyl chloride, ethyl oxalyl chloride, methyl chloroformate, ethyl chloroformate, benzoic anhydride, benzoyl chloride, or
  • the starting material for the process of the present invention i.e. (2S, 3R)-I- (dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol (compound 4), was prepared by reacting (2S)-3-(dimethylairrino)-l-(3-methoxyphenyl)-2-methyl-l- propanone (compound 3) with ethylmagnesium chloride in THF under Grignard reaction conditions.
  • the reaction of the Grignard reagent with the ketone compound (3) introduces a second asymmetric carbon atom.
  • the Grignard reaction of (2S)-3-(dimethylamino)-l-(3- methoxyphenyl)-2-methyl-l-propanone (compound 3) with an ethylmagnesium halide is highly stereospecific.
  • the optical purity of the starting compound (3) was found to be 98.0%.
  • Compound (4) was analysed to comprise 96.8% of the desired (2S,3R) enantiomer, less than 0.4% of the (2S,3S) enantiomer and 3.0% of the (2R,3S) enantiomer.
  • Table 1 lists the stereoisomeric purity of the compound (4) when prepared as outlined above.
  • Compound (4) can be converted into compound (5) by acylating compound (4) with trifluoroacetic anhydride and subsequent hydrogenolysis over a palladium catalyst, using 2-methyltetrahydrofuran as a solvent, in a "one pot synthesis" procedure.
  • optical purity of starting compound (4) was 96.8% enantiomer (2S,3R). It was found that hydrogenolysis after acylation of compound (4) is highly stereospecific to give the desired enantiomer (2R,3R)-enantiomer of compound (5) with an optical purity of 96.3%.
  • the reaction mixture is heated to reflux temperature and stirred and refluxed for 5 hours.
  • the reaction mixture is allowed to cool to 20 0 C, and water (730 ml) and toluene (146 ml) are added.
  • the upper organic layer is discarded and an aqueous NaOH solution (50% w/w, 175.2 ml) is added to the water layer while stirring for 10 minutes and keeping the temperature below 25 0 C. After 10 minutes the layers are allowed to separate, the upper organic layer is isolated and washed with water (219 ml). The organic layer is isolated and concentrated to obtain 3-(dimethylamino)-l- (3-methoxyphenyl)-2-methyl-l-propanone as on oily residue (294.9 g).
  • Compound (3) prepared according to procedure of Example 2 typically has an enantiomeric purity of 97% or higher.
  • Compound (4) prepared according to the procedure of Example 4 comprises 96.8% of the desired (2S,3R) enantiomer, less than 0.4% of the (2S,3S) enantiomer and 3.0% of the (2R,3S) enantiomer.
  • Example 4 Synthesis of (2fl,3/O-3-(3-methoxyphenyl)-N,N,2- trimethylpentanamine (5)
  • Compound (5) prepared according to the procedure of Example 5 comprises 96.3% of the desired (2R,3R) enantiomer, 2.5% of the (2S,3S) enantiomer and 1.2% of the (2R,3S) enantiomer.
  • Compound (6) prepared according to the procedure of Example 6 comprises 99.7% of the desired (2R,3R) enantiomer, and 0.3% of the (2R,3S) enantiomer.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention relates to an improved process for the preparation of (2R,3R)-3- (3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.

Description

PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)- N,N,2-TRIMETHYLPENTANAMINE
The present invention relates to an improved process for the preparation of (2R,3R)-3- (3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.
Tapentadol is the INN (International Non-proprietary Name) of 3-[(lR,2R)-3- (dimethylamino)-l-ethyl-2-methylpropyl]phenol monohydrochloride which compound is represented by the formula :
tapentadol
Figure imgf000002_0001
The chemical structure of tapentadol has been disclosed in EP-A-0, 693,475 as compound (+21). The synthesis of tapentadol is described in Example 1 and Example 24 steps 1 to 3 and is outlined below using the compound numbers as mentioned in said EP-A-0,693,475.
Figure imgf000002_0002
(2S,3S) + (2R,3R)
Figure imgf000002_0003
(2R,3R) (2R,3R)
Figure imgf000003_0001
(2R.3R) (1R.2R)
The synthetic precursor of tapentadol in the above scheme is (2R,3R)-3-(3-methoxy- phenyl)-N,N,2-trimethylpentanamine (intermediate (+23) in the above scheme) which can be obtained by removing the tertiary hydroxy group of (2lSr,3^)-l-(dimethylamino)- 3-(3-methoxyphenyl)-2-methyl-3-pentanol by consecutive conversion into the corresponding halogenide with thionyl chloride and subsequent removal of the Cl by treatment with zinc borohydride, zinc cyanoborohydride and/or tin cyanoborohydride. This procedure has the disadvantage that the halogenide compound is prepared using an excess amount of thionyl chloride which is an aggressive chlorinating agent. Moreover the hydrogenation reagents such as zinc borohydride, zinc cyanoborohydride and tin cyanoborohydride present a considerable fire and health danger when used on an industrial scale.
WO-2004/108658 discloses an alternative process for obtaining (2R,3R)-3-(3-methoxy- phenyl)-N,N,2-trimethylpentanamine by converting (2S,3S)-l-(dimethylamino)-3-(3- methoxyphenyl)-2-methyl-3-pentanol into a mixture of (2R,3R) and (2R,3S)-3-(3- methoxyphenyl)-N,N,2-trimethylpentanamine as outlined below.
Figure imgf000003_0002
(2S.3S) (Z)-(2R) + (E)-(2R) (2R.3R) (2R.3S)
The resulting mixture of (2R.3R) and (2R,3S)-3-(3-methoxyphenyl)-N,N,2-trimethyl- pentanamine has to be separated into its individual stereoisomers in order to obtain the desired (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine, which can then be converted into tapentadol by e.g. heating with concentrated hydrobromic acid as described in EP-A-0,693,475. WO-2005/000788 discloses an alternative process for obtaining (2R,3R)-3-(3-methoxy- phenyl)-N,N,2-trimethylpentanamine by converting (2S,3S)-l-(dimethylamino)-3-(3- methoxyphenyl)-2-methyl-3-pentanol into a mixture of (2R,3R) and (2R,3S)-3-(3- methoxyphenyl)-N,N,2-trimethylpentanamine as outlined below.
heterogeneous catalyst
Figure imgf000004_0001
Figure imgf000004_0002
(2S,3S) (Z)-(2S) + (E)-(2S)
catalyst
H2 ΔT / ΔP
1) heterogeneous catalyst
2) catalyst / H2 / ΔT / ΔP
"one pot synthesis"
Figure imgf000004_0003
(2R.3R) (2R.3S)
The resulting mixture of (2R,3R) and (2R,3S)-3-(3-methoxyphenyl)-N,N,2- trimethylpentanamine has to be separated into its individual stereoisomers in order to obtain the desired (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine, which can then be converted into tapentadol by e.g. heating with concentrated hydrobromic acid as described in EP-A-0,693,475.
Both alternative processes of WO-2004/108658 and WO-2005/00078 have the disadvantage that [3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine is obtained as a mixture of the (2R,3R) and (2R,3S) stereoisomers which have to be separated in order to obtain the desired (2R,3R) stereoisomer. The undesired (2R,3S) stereoisomer cannot be converted into the desired (2R,3R) stereoisomer and has to be disposed of as chemical waste, which is economically undesirable for any industrial scale production.
The object of the present invention is to provide an improved method for the synthesis of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine which is more convenient and more efficient than the previously known methods. - A -
The present invention achieves this object by providing an improved process for the preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine, or an acid addition salt thereof, which is characterized by the steps of a) acylating (2lSr,3R)-l-(dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol
Figure imgf000005_0001
with an acylating agent; b) stereoselective hydrogenolysis of the thus obtained compound (III)
Figure imgf000005_0002
using a suitable catalyst in a reaction-inert solvent in the presence of hydrogen; and c) optionally converting the thus obtained (2R,3R)-3-(3-methoxyphenyl)-N,N,2- trimethylpentanamine
Figure imgf000005_0003
into an acid addition salt.
The acylating agent of step a) is an organic acyl halide or organic acid anhydride selected from acetic anhydride, acetyl chloride, trifluoroacetic anhydride, chloroacetic anhydride, chloro acetylchloride, dichloroacetic anhydride, trichloroacetic anhydride, benzoic anhydride, benzoyl chloride, phthalic anhydride, phtaloyl dichloride, terephthaloyldichloride, succinic anhydride, succinyl chloride, ethyl oxalyl chloride, methyl oxalyl chloride, Meldrum's acid, ethyl chloroformate, methylchloroformate, acetylsalicyloyl chloride, or any other suitable acylating agent. The acylation reaction of step a) may be performed in the presence of a suitable base, such as e.g. sodium carbonate, potassium carbonate or triethylamine, to capture the acid liberated during the reaction
The catalyst of step b) is selected from a palladium catalyst, or any other suitable catalyst such as e.g. Raney nickel, platinum, platinum on carbon, ruthenium or rhodium on carbon.
The palladium (Pd) catalyst may be a homogeneous Pd catalyst, such as for example Pd(OAc)2, PdCl2, Pd(PPh3)4, Pd(PPh3)2Cl2, Pd2(dba)3 (tris(dibenzylidene acetone) dipalladium), palladium thiomethylphenylglutaramide metallacycle and the like, or a heterogeneous Pd catalyst, such as for example palladium on charcoal, palladium on metal oxides, palladium on zeolites. Preferably, the palladium catalyst is a heterogeneous Pd catalyst, more preferably palladium on charcoal or palladium on carbon (Pd/C). Pd/C is a recoverable catalyst, is stable and relatively inexpensive. It can be easily separated (filtration) from the reaction mixture thereby reducing the risk of Pd traces in the final product. The use of Pd/C also avoids the need for ligands, such as for example phosphine ligands, which are expensive, toxic and contaminants of the synthesized products.
The reaction-inert solvent of step b) is selected from diethyl ether, tetrahydrofuran, 2-methyltetrahydrofuran or mixtures thereof.
In an embodiment of the present invention, steps a) and b) are executed as a "one pot synthesis" procedure.
The present invention also relates to novel compounds of formula (III)
Figure imgf000006_0001
The acyl group in compounds of formula (III) represents CH3-CO-, CF3-CO-, CH2Cl-CO-, CHCl2-CO-, CCl3-CO-, CH3O-CO-CO-, CH3O-CO-, CH3CH2O-CO-, CH3CH2O-CO-CO, phenyl-CO-, or meta-CH3COO-phenyl-CO- when the acylating agent used to prepared the compounds of formula (III) as set out above is selected from acetic anhydride, acetyl chloride, trifluoroacetic anhydride, chloroacetic anhydride, chloro acetylchloride, dichloroacetic anhydride, trichloroacetic anhydride, methyl oxalyl chloride, ethyl oxalyl chloride, methyl chloroformate, ethyl chloroformate, benzoic anhydride, benzoyl chloride, or acetylsalicyloyl chloride.
The starting material for the process of the present invention, i.e. (2S, 3R)-I- (dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol (compound 4), was prepared by reacting (2S)-3-(dimethylairrino)-l-(3-methoxyphenyl)-2-methyl-l- propanone (compound 3) with ethylmagnesium chloride in THF under Grignard reaction conditions.
Figure imgf000007_0001
The reaction of the Grignard reagent with the ketone compound (3) introduces a second asymmetric carbon atom. The Grignard reaction of (2S)-3-(dimethylamino)-l-(3- methoxyphenyl)-2-methyl-l-propanone (compound 3) with an ethylmagnesium halide is highly stereospecific. The optical purity of the starting compound (3) was found to be 98.0%. Compound (4) was analysed to comprise 96.8% of the desired (2S,3R) enantiomer, less than 0.4% of the (2S,3S) enantiomer and 3.0% of the (2R,3S) enantiomer. Table 1 lists the stereoisomeric purity of the compound (4) when prepared as outlined above.
Compound (4) can be converted into compound (5) by acylating compound (4) with trifluoroacetic anhydride and subsequent hydrogenolysis over a palladium catalyst, using 2-methyltetrahydrofuran as a solvent, in a "one pot synthesis" procedure.
Figure imgf000007_0002
The optical purity of starting compound (4) was 96.8% enantiomer (2S,3R). It was found that hydrogenolysis after acylation of compound (4) is highly stereospecific to give the desired enantiomer (2R,3R)-enantiomer of compound (5) with an optical purity of 96.3%.
Additional salt formation of compound (5) further improves the optical purity of compound (5). For example, a diastereomeric excess of > 99% was achieved by converting compound (5) to its hydrochloric acid salt compound (6) using 2-propanol as crystallization solvent.
Figure imgf000008_0001
(5) (6)
Table 1 : stereoisomeric purity of compounds (4), (5) and (6)
Figure imgf000008_0003
Experimental part.
Example 1 : Synthesis of 3-(dimethylamino)-l-(3-methoxyphenyl)-2-methyl-l- propanone (1)
Figure imgf000008_0002
A mixture of l-(3-methoxyphenyl)-l-propanone (240 g) in 2-propanol (584 ml) is stirred at ambient temperature. Dimethylamine hydrochloride (238.3 g) is added, followed by paraformaldehyde (109.5 g) and an aqueous HCl solution (26.5 ml, 35% w/w). The reaction mixture is heated to reflux temperature and stirred and refluxed for 5 hours. The reaction mixture is allowed to cool to 200C, and water (730 ml) and toluene (146 ml) are added. The upper organic layer is discarded and an aqueous NaOH solution (50% w/w, 175.2 ml) is added to the water layer while stirring for 10 minutes and keeping the temperature below 250C. After 10 minutes the layers are allowed to separate, the upper organic layer is isolated and washed with water (219 ml). The organic layer is isolated and concentrated to obtain 3-(dimethylamino)-l- (3-methoxyphenyl)-2-methyl-l-propanone as on oily residue (294.9 g).
Example 2 : Synthesis and isolation of (2S)-3-(dimethylamino)-l-(3- methoxyphenyl)-2-methyl-l-propanone (3)
Figure imgf000009_0001
a) Compound (1) (114.7 g) in ethanol (50 ml) is added to a solution of L-(-)-dibenzoyl- tartaric acid monohydrate (188.2 g) in ethanol (950 ml) and the reaction mixture is warmed to 38°C and stirred for 48 hours at 38°C. The reaction mixture is then allowed to cool to 22°C and stirred for 14 hours at 22°C. The precipitate is filtered off, washed twice with ethanol (50 ml) and dried in vacuo at a temperature of 400C, yielding compound (2) (207.5 g).
b) Compound (2) (202.9 g) is suspended in methyl- tert-buty Ie ther (1050 ml) and diethylamine (72.4 ml) is added. The suspension is stirred for 3 hours at ambient temperature and the precipitate is removed by filtration. The filtrate is concentrated under reduced pressure, yielding (2S)-3-(dimethylamino)-l-(3-methoxyphenyl)-2- methyl-1-propanone (3) as an oil (73.9 g). An alternative procedure to procedure b : c) Compound (2) (312.8 g) is suspended in 2-methyltetrahydrofuran (405 ml) and water (540 ml). Aqueous NH4OH (93 ml, 51% w/w) is added and the mixture is then allowed to stir for 30 minutes. The layers are separated and the isolated upper organic layer is washed with water (100 ml), then concentrated under reduced pressure, yielding (2S)-3- (dimethylamino)-l-(3-methoxyphenyl)-2-methyl-l-propanone (3) as a yellow oil (109.O g).
Compound (3) prepared according to procedure of Example 2 typically has an enantiomeric purity of 97% or higher.
Example 3 : Synthesis of (2£3/?)-l-(dimethylamino)-3-(3-methoxyphenvl)-2- methvl-3-pentanol (4)
Figure imgf000010_0001
(3) (4)
A solution of EtMgCl in THF (242 ml, 2M) was stirred and cooled to 2°C.
Compound (3) (101.3 g, 0.44 mole) was slowly added over a period of 50 minutes while the temperature of the reaction mixture was kept below 25°C. The mixture was stirred for 3 hours at 22°C, then slowly quenched in a mixture of ice- water (352 ml) and acetic acid (63.9 ml). The mixture was stirred for 30 minutes at ambient temperature, then aqueous NH4OH (98.8 ml, 51% w/w) was added and then allowed to stir for 10 minutes at ambient temperature.
The layers are separated and the isolated upper organic layer is then washed with water (44 ml), then concentrated under reduced pressure to dryness, yielding (2S,3R)-1-
(dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol (4) as a yellow oil which solidifies upon standing at ambient temperature (112.0 g).
Compound (4) prepared according to the procedure of Example 4, comprises 96.8% of the desired (2S,3R) enantiomer, less than 0.4% of the (2S,3S) enantiomer and 3.0% of the (2R,3S) enantiomer. Example 4 : Synthesis of (2fl,3/O-3-(3-methoxyphenyl)-N,N,2- trimethylpentanamine (5)
Figure imgf000011_0001
a) A solution of compound (4) (50.3 g) dissolved in 2-methyltetrahydrofuran (120 ml) was stirred and cooled to 5°C. Then trifluoroacetic anhydride (30.6 ml) was added slowly over a period of 10 minutes while the temperature of the reaction mixture was kept below 200C. After addition, the reaction mixture was allowed to stir for 1 hour at 200C.
b) Palladium 10% on activated carbon (50% wetted) (2.52 g) was added and the reaction mixture was stirred at 800 rpm and pressurized to 2 atmosphere (202.65 kPa) with hydrogen gas. The reaction mixture was heated to 400C and stirred for 4 hours at 400C. The mixture was allowed to cool to 200C and filtered under nitrogen atmosphere. The filter was washed with 2-methyltetrahydrofuran (10 ml). Water (160 ml) was added to the filtrate and the mixture was stirred, then an aqueous NaOH solution (28.6 ml, 50% w/w) was added over a period of 10 minutes while the temperature was kept below 200C. The organic and water layer were allowed to separate, the organic layer was isolated and washed with water (50 ml), and concentrated under reduced pressure to dryness, yielding (2i?,3i?)-3-(3-methoxyphenyl)-N,N,2-trimethyl- pentanamine (5) as a colourless oil (46.10 g).
Compound (5) prepared according to the procedure of Example 5 comprises 96.3% of the desired (2R,3R) enantiomer, 2.5% of the (2S,3S) enantiomer and 1.2% of the (2R,3S) enantiomer.
Using an analogous procedure as described in a) but replacing trifluoroacetic anhydride with acetyl chloride or ethyl oxalyl chloride and adding triethylamine to the reaction mixture, yielded compounds (7) and (8) respectively. Said compounds (7) and (8) were converted into compound (8) using the above procedure b).
Figure imgf000012_0001
Example 5 : Synthesis of (2fl,3/O-3-(3-methoxyphenyl)-N,N,2- trimethylpentanamine monohydrochloride (6)
Figure imgf000012_0002
Compound (5) (23.0 g) was dissolved in 2-propanol (50 ml) and stirred at ambient temperature. Then a solution of HCl in 2-propanol (20.3 g , 17.9% w/w) was added slowly over a period of 5 minutes. The mixture was seeded with compound (6) (10 mg) and the reaction mixture was allowed to stir at ambient temperature for 1 hour. The mixture was cooled to a temperature of 00C and stirred for 4 hours. The precipitate was filtered off, washed with 2-propanol (5 ml) and dried under vacuo, yielding (2R,3R)-3- (3-methoxyphenyl)-N,N,2-trimethylpentanamine monohydrochloride (6) as a white solid ( 22.9 g).
Compound (6) prepared according to the procedure of Example 6 comprises 99.7% of the desired (2R,3R) enantiomer, and 0.3% of the (2R,3S) enantiomer.

Claims

Claims
1. A process for preparing (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethyl- pentanamine, or an acid addition salt thereof, comprising the steps of a) acylating (2S,3^)-l-(dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3- pentanol
Figure imgf000013_0001
with an acylating agent; b) hydrogenolysis of the thus obtained compound (III)
Figure imgf000013_0002
using a suitable catalyst in a reaction-inert solvent in the presence of hydrogen; and c) optionally converting the thus obtained (2i?,3i?)-3-(3-methoxyphenyl)-N,N,2- trimethylpentanamine
Figure imgf000013_0003
into an acid addition salt.
2. A process according to claim 1 wherein the acylating agent of step a) is an organic acyl halide or organic acid anhydride.
3. A process according to claim 2 wherein the organic acyl halide or organic acid anhydride is selected from acetic anhydride, acetyl chloride, trifluoroacetic anhydride, chloroacetic anhydride, chloro acetylchloride, dichloroacetic anhydride, trichloroacetic anhydride, benzoic anhydride, benzoyl chloride, phthalic anhydride, phtaloyl dichloride, terephthaloyldichloride, succinic anhydride, succinyl chloride, ethyl oxalyl chloride, methyl oxalyl chloride, Meldrum's acid, ethyl chloroformate, methylchloroformate, or acetylsalicyloyl chloride.
4. A process according to claim 3 wherein the acid anhydride is trifluoroacetic anhydride.
5. A process according to claim 3 wherein the organic acyl halide is acetyl chloride or ethyl oxalyl chloride.
6. A process according to any of claims 1 to 5 wherein the catalyst of step b) is selected from Raney nickel, palladium, palladium on carbon, platinum, platinum on carbon, ruthenium or rhodium on carbon, or any other suitable catalyst.
7. A process according to claim 6 wherein the catalyst is palladium on carbon.
8. A process according to any of claims 1 to 7 wherein the reaction-inert solvent of step b) is selected from diethyl ether, tetrahydrofuran, 2-methyltetrahydrofuran or mixtures thereof.
9. A process according to any of claims 1 to 8 wherein (2i?,3i?)-3-(3-methoxyphenyl)- N,N,2-trimethylpentanamine is converted into its corresponding hydrochloric acid addition salt.
10. A process according to any of the preceding claims wherein steps a) and b) are carried out in a one -pot reaction.
11. A compound of formula (III) wherein acyl represents CH3-CO-, CF3-CO-, CH2Cl-CO-, CHCl2-CO-, CCl3-CO-, CH3O-CO-, CH3CH2O-CO-, CH3O-CO-CO,
CH3CH2O-CO-CO-, phenyl-CO-, or meta-CH3COO-phenyl-CO-.
(πi) .
Figure imgf000014_0001
12. A compound of formula (III) as claimed in claim 11 wherein acyl represents CF3-CO-.
13. A compound of formula (III) as claimed in claim 11 wherein acyl represents CH3-CO- or CH3CH2O-CO-CO-.
PCT/EP2007/057559 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine Ceased WO2008012283A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
EP07787803A EP2046726B1 (en) 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
DE602007004494T DE602007004494D1 (en) 2006-07-24 2007-07-23 Preparation of (2R, 3R) -3- (3-methoxy-phenyl) -N, N, 2-trimethylpentanamine
PL07787803T PL2046726T3 (en) 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
HR20100197T HRP20100197T1 (en) 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
HK09111685.8A HK1134280B (en) 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
KR1020097000899A KR101370398B1 (en) 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
CA2656696A CA2656696C (en) 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
CN2007800284726A CN101495447B (en) 2006-07-24 2007-07-23 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine
JP2009521242A JP5208933B2 (en) 2006-07-24 2007-07-23 Production of (2R, 3R) -3- (3-methoxyphenyl) -N, N, 2-trimethylpentanamine
US12/374,894 US8138376B2 (en) 2006-07-24 2007-07-23 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine
MX2009000911A MX2009000911A (en) 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentana mine.
AT07787803T ATE455752T1 (en) 2006-07-24 2007-07-23 PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2-TRIMETHYLPENT NAMIN
AU2007278224A AU2007278224C1 (en) 2006-07-24 2007-07-23 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine
EA200970147A EA015003B1 (en) 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
BRPI0714671A BRPI0714671B8 (en) 2006-07-24 2007-07-23 PREPARATION OF (2R,3R)-3-(3-METHOXYPHENYL)-N,N,2-TRIMETHYLPENTANAMINE AND INTERMEDIATE COMPOUNDS
DK07787803.1T DK2046726T3 (en) 2006-07-24 2007-07-23 Preparation of (2R, 3R) -3-3-Methoxyphenyl) -N, N, 2-trimethylpentanamine
IL196627A IL196627A (en) 2006-07-24 2009-01-21 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
US13/397,186 US8440863B2 (en) 2006-07-24 2012-02-15 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117708 2006-07-24
EP06117708.5 2006-07-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/374,894 A-371-Of-International US8138376B2 (en) 2006-07-24 2007-07-23 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine
US13/397,186 Division US8440863B2 (en) 2006-07-24 2012-02-15 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine

Publications (1)

Publication Number Publication Date
WO2008012283A1 true WO2008012283A1 (en) 2008-01-31

Family

ID=37772663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/057559 Ceased WO2008012283A1 (en) 2006-07-24 2007-07-23 Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine

Country Status (21)

Country Link
US (2) US8138376B2 (en)
EP (1) EP2046726B1 (en)
JP (1) JP5208933B2 (en)
KR (1) KR101370398B1 (en)
CN (1) CN101495447B (en)
AT (1) ATE455752T1 (en)
AU (1) AU2007278224C1 (en)
BR (1) BRPI0714671B8 (en)
CA (1) CA2656696C (en)
CY (1) CY1110075T1 (en)
DE (1) DE602007004494D1 (en)
DK (1) DK2046726T3 (en)
EA (1) EA015003B1 (en)
ES (1) ES2339403T3 (en)
HR (1) HRP20100197T1 (en)
IL (1) IL196627A (en)
MX (1) MX2009000911A (en)
PL (1) PL2046726T3 (en)
PT (1) PT2046726E (en)
SI (1) SI2046726T1 (en)
WO (1) WO2008012283A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20092110A1 (en) * 2009-12-01 2011-06-02 Archimica Srl NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND ITS INTERMEDIATES.
WO2011080736A1 (en) 2009-12-29 2011-07-07 Mapi Pharma Hk Limited Intermediate compounds and processes for the preparation of tapentadol and related compounds
WO2011107876A2 (en) 2010-03-05 2011-09-09 Actavis Group Ptc Ehf Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
WO2011092719A3 (en) * 2010-02-01 2011-09-22 Ind-Swift Laboratories Limited Process for preparing 1 -phenyl-3 -dimethylaminopropane derivatives
WO2011128784A2 (en) 2010-04-05 2011-10-20 Actavis Group Ptc Ehf Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
CZ302993B6 (en) * 2010-12-30 2012-02-08 Zentiva, K.S. Process for preparing (2R,3R)-N,N-dimethyl-3-(hydroxyphenyl)-2-methylpentylamine (tapentadol)
WO2012038974A1 (en) 2010-09-20 2012-03-29 Ind-Swift Laboratories Limited Process for preparing l-phenyl-3-dimethylaminopropane derivative
CZ303115B6 (en) * 2010-12-30 2012-04-11 Zentiva, K.S. Process for preparing (2R,3R)-N,N-dimethyl-3-(3-hydroxyphenyl)-2-methylpentylamine
WO2012089181A1 (en) * 2010-12-30 2012-07-05 Zentiva, K.S. O-substituted (2r,3r)-3-(3-hydroxyphenyl)-2-methyl-4-pentenoic acids and a method of obtaining the same
WO2012089177A1 (en) * 2010-12-30 2012-07-05 Zentiva, K.S. Method of producing (2r,3r)-na-dimethyl-3-(3-hydroxyphenyi)-2-methylpentylamine (tapentadol)
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
WO2012146978A2 (en) 2011-04-28 2012-11-01 Actavis Group Ptc Ehf A novel process for the preparation of tapentadol or a pharmaceutically acceptable salt thereof
WO2013090161A1 (en) 2011-12-12 2013-06-20 Boehringer Ingelheim International Gmbh Stereoselective synthesis of tapentadol and its salts
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
WO2015075678A1 (en) 2013-11-21 2015-05-28 Unimark Remedies Ltd. A novel process for the preparation of 1-phenyl-3-aminopropane derivatives
WO2015091068A1 (en) 2013-12-16 2015-06-25 Farma Grs, D.O.O. Crystalline forms of tapentadol intermediate
WO2015117576A1 (en) 2014-02-04 2015-08-13 Zentiva, K.S. A solid form of tapentadol maleate and a method of its preparation
US9446008B2 (en) 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
US9914695B2 (en) 2015-07-10 2018-03-13 Mallinckrodt Llc Two-step process for preparing 3-substituted phenylalkylamines
WO2019035775A1 (en) * 2017-08-18 2019-02-21 Saneca Pharmaceuticals A.S. Method for the preparation of tapentadol and its intermediates
WO2019238267A1 (en) 2018-06-15 2019-12-19 Pharmathen S.A. A novel process for the preparation of tapentadol
US10898452B2 (en) 2016-09-23 2021-01-26 Gruenenthal Gmbh Stable formulation for parenteral administration of Tapentadol
US11013701B2 (en) 2015-03-27 2021-05-25 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
US11547678B2 (en) 2011-03-04 2023-01-10 Gruenenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration
EP4116288A1 (en) 2021-07-08 2023-01-11 KRKA, d.d., Novo mesto Racemization of (s) and/or (r)-3-(dimethylamino)-1-(3-methoxyphenyl)-2-methylpropan-1- one and its mixtures

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI401237B (en) * 2006-07-24 2013-07-11 Preparation of 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
CN102002065B (en) * 2009-09-02 2014-09-10 上海特化医药科技有限公司 Method for preparing tapentadolhydrochloride and intermediate thereof
IT1401109B1 (en) * 2010-07-02 2013-07-12 Archimica Srl NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND ITS INTERMEDIATES.
EP3650439B1 (en) * 2010-07-23 2021-02-24 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CN102477016B (en) * 2010-11-26 2014-12-17 中国医学科学院药物研究所 Synthesis and application of intermediate of tapentadol
CN102617501A (en) * 2011-01-31 2012-08-01 中国科学院上海药物研究所 Substituted valeramide compound, preparation method and application thereof
CN103501775A (en) * 2011-03-04 2014-01-08 格吕伦塔尔有限公司 Parenteral administration of tapentadol
CN102206164A (en) * 2011-04-11 2011-10-05 中国药科大学 Method for preparing tapentadol intermediate
EP2674414A1 (en) 2012-06-15 2013-12-18 Siegfried AG Method for the preparation of 1-aryl-1-alkyl-3-dialkylaminopropane compounds
CN103159633B (en) * 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 The preparation method of tapentadol hydrochloride and the compound for the preparation of tapentadol hydrochloride
CN104725287A (en) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 Preparation method and application of para-toluenesulfonate
CN106278915A (en) * 2015-05-19 2017-01-04 重庆圣华曦药业股份有限公司 A kind of method preparing tapentadol hydrochloride intermediate
AU2020245333A1 (en) * 2019-03-28 2021-10-28 Council Of Scientific And Industrial Research Process for the preparation of tapentadol and analogs thereof
EP4269384A1 (en) 2022-04-26 2023-11-01 KRKA, d.d., Novo mesto Method for crystallizing tapentadol intermediate, tapentadol intermediate of high purity, method of making tapentadol and tapentadol of high purity
CN119192000B (en) * 2024-11-26 2025-07-15 苏州盛迪亚生物医药有限公司 Method for preparing tapentadol or its pharmaceutically acceptable salt by continuous flow reaction
CN119176758B (en) * 2024-11-26 2025-05-09 苏州盛迪亚生物医药有限公司 A method for preparing tapentadol or its pharmaceutically acceptable salt by solid-support catalysis
CN119191999A (en) * 2024-11-26 2024-12-27 苏州盛迪亚生物医药有限公司 A method for preparing tapentadol or its pharmaceutically acceptable salt

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811582A (en) * 1996-03-13 1998-09-22 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-amine compounds as pharmaceutical active ingredients
US6344558B1 (en) * 1994-07-23 2002-02-05 Gruenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect
WO2004108658A1 (en) * 2003-06-06 2004-12-16 Grünenthal GmbH Method for the production of substituted 3-aryl-butyl amine compounds
WO2005000788A1 (en) * 2003-06-23 2005-01-06 Grünenthal GmbH Method for dehydrating substituted 4-dimethylamino-2-aryl-butan-2-ol compounds and method for producing substituted dimethyl-(3-aryl-butyl)-amine compounds by means of heterogeneous catalysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60188333A (en) * 1984-03-07 1985-09-25 Ihara Chem Ind Co Ltd Method for producing halogenated benzenes
ES2278664T3 (en) * 2000-09-14 2007-08-16 Firmenich Sa USE OF Unsaturated ESTERS AS PERFUMING INGREDIENTS.
TWI401237B (en) * 2006-07-24 2013-07-11 Preparation of 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344558B1 (en) * 1994-07-23 2002-02-05 Gruenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect
US5811582A (en) * 1996-03-13 1998-09-22 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-amine compounds as pharmaceutical active ingredients
WO2004108658A1 (en) * 2003-06-06 2004-12-16 Grünenthal GmbH Method for the production of substituted 3-aryl-butyl amine compounds
WO2005000788A1 (en) * 2003-06-23 2005-01-06 Grünenthal GmbH Method for dehydrating substituted 4-dimethylamino-2-aryl-butan-2-ol compounds and method for producing substituted dimethyl-(3-aryl-butyl)-amine compounds by means of heterogeneous catalysis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BEILSTEIN [cdrom] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; 2004, XP002423030, Database accession no. RID:9554854 *
DATABASE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Farnkfurtam Main, DE; 1986, XP002423029, Database accession no. RID:2562465 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SPALVA, E. A.: "Relations between structure and anesthetic activity of some esters of aralkanols", XP002423028, retrieved from STN Database accession no. 1964:85583 *
FARMAKOLOGIYA I TOKSIKOLOGIYA (MOSCOW) , 26(5), 606-11 CODEN: FATOAO; ISSN: 0014-8318, 1963 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512060B2 (en) 2009-09-22 2016-12-06 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
US8981154B2 (en) 2009-09-22 2015-03-17 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
WO2011067714A1 (en) 2009-12-01 2011-06-09 Archimica Srl New process for the preparation of tapentadol and intermediates thereof
ITMI20092110A1 (en) * 2009-12-01 2011-06-02 Archimica Srl NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND ITS INTERMEDIATES.
CN102711461A (en) * 2009-12-29 2012-10-03 Mapi医药公司 Intermediate compounds and processes for the preparation of tapentadol and related compounds
WO2011080736A1 (en) 2009-12-29 2011-07-07 Mapi Pharma Hk Limited Intermediate compounds and processes for the preparation of tapentadol and related compounds
US8410176B2 (en) 2009-12-29 2013-04-02 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of tapentadol and related compounds
WO2011092719A3 (en) * 2010-02-01 2011-09-22 Ind-Swift Laboratories Limited Process for preparing 1 -phenyl-3 -dimethylaminopropane derivatives
WO2011107876A2 (en) 2010-03-05 2011-09-09 Actavis Group Ptc Ehf Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
WO2011128784A2 (en) 2010-04-05 2011-10-20 Actavis Group Ptc Ehf Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
WO2011128784A3 (en) * 2010-04-05 2012-01-19 Actavis Group Ptc Ehf Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
WO2012038974A1 (en) 2010-09-20 2012-03-29 Ind-Swift Laboratories Limited Process for preparing l-phenyl-3-dimethylaminopropane derivative
US8552219B2 (en) 2010-09-20 2013-10-08 Ind-Swift Laboratories Limited Process for preparing L-phenyl-3-dimethylaminopropane derivative
CZ302993B6 (en) * 2010-12-30 2012-02-08 Zentiva, K.S. Process for preparing (2R,3R)-N,N-dimethyl-3-(hydroxyphenyl)-2-methylpentylamine (tapentadol)
WO2012089181A1 (en) * 2010-12-30 2012-07-05 Zentiva, K.S. O-substituted (2r,3r)-3-(3-hydroxyphenyl)-2-methyl-4-pentenoic acids and a method of obtaining the same
CZ303115B6 (en) * 2010-12-30 2012-04-11 Zentiva, K.S. Process for preparing (2R,3R)-N,N-dimethyl-3-(3-hydroxyphenyl)-2-methylpentylamine
WO2012089177A1 (en) * 2010-12-30 2012-07-05 Zentiva, K.S. Method of producing (2r,3r)-na-dimethyl-3-(3-hydroxyphenyi)-2-methylpentylamine (tapentadol)
US11547678B2 (en) 2011-03-04 2023-01-10 Gruenenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration
US9446008B2 (en) 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
WO2012146978A2 (en) 2011-04-28 2012-11-01 Actavis Group Ptc Ehf A novel process for the preparation of tapentadol or a pharmaceutically acceptable salt thereof
WO2013090161A1 (en) 2011-12-12 2013-06-20 Boehringer Ingelheim International Gmbh Stereoselective synthesis of tapentadol and its salts
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
WO2015075678A1 (en) 2013-11-21 2015-05-28 Unimark Remedies Ltd. A novel process for the preparation of 1-phenyl-3-aminopropane derivatives
WO2015091068A1 (en) 2013-12-16 2015-06-25 Farma Grs, D.O.O. Crystalline forms of tapentadol intermediate
WO2015117576A1 (en) 2014-02-04 2015-08-13 Zentiva, K.S. A solid form of tapentadol maleate and a method of its preparation
US11013701B2 (en) 2015-03-27 2021-05-25 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
US9914695B2 (en) 2015-07-10 2018-03-13 Mallinckrodt Llc Two-step process for preparing 3-substituted phenylalkylamines
US10898452B2 (en) 2016-09-23 2021-01-26 Gruenenthal Gmbh Stable formulation for parenteral administration of Tapentadol
WO2019035775A1 (en) * 2017-08-18 2019-02-21 Saneca Pharmaceuticals A.S. Method for the preparation of tapentadol and its intermediates
WO2019238267A1 (en) 2018-06-15 2019-12-19 Pharmathen S.A. A novel process for the preparation of tapentadol
EP4116288A1 (en) 2021-07-08 2023-01-11 KRKA, d.d., Novo mesto Racemization of (s) and/or (r)-3-(dimethylamino)-1-(3-methoxyphenyl)-2-methylpropan-1- one and its mixtures

Also Published As

Publication number Publication date
IL196627A0 (en) 2009-11-18
CN101495447B (en) 2013-05-29
KR20090033444A (en) 2009-04-03
EA015003B1 (en) 2011-04-29
PL2046726T3 (en) 2010-06-30
KR101370398B1 (en) 2014-03-05
MX2009000911A (en) 2009-02-04
HK1134280A1 (en) 2010-04-23
ATE455752T1 (en) 2010-02-15
BRPI0714671B1 (en) 2020-09-24
CA2656696C (en) 2013-06-11
BRPI0714671B8 (en) 2023-03-21
US20120142970A1 (en) 2012-06-07
BRPI0714671A2 (en) 2013-05-07
CN101495447A (en) 2009-07-29
EP2046726B1 (en) 2010-01-20
HRP20100197T1 (en) 2010-05-31
CA2656696A1 (en) 2008-01-31
CY1110075T1 (en) 2015-01-14
IL196627A (en) 2013-06-27
AU2007278224C1 (en) 2012-06-21
SI2046726T1 (en) 2010-05-31
JP2009544658A (en) 2009-12-17
US8138376B2 (en) 2012-03-20
PT2046726E (en) 2010-04-15
US8440863B2 (en) 2013-05-14
AU2007278224A1 (en) 2008-01-31
US20090312578A1 (en) 2009-12-17
JP5208933B2 (en) 2013-06-12
EA200970147A1 (en) 2009-08-28
AU2007278224B2 (en) 2011-09-15
DE602007004494D1 (en) 2010-03-11
DK2046726T3 (en) 2010-05-10
EP2046726A1 (en) 2009-04-15
ES2339403T3 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
EP2046726B1 (en) Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
US8263809B2 (en) Preparation of 3-[(1R,2R)-3-(dimethylamino)-1ethyl-2-methylpropyl]phenol
HK1134280B (en) Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
HK1130247B (en) Preparation of 3-[(1r,2r)-3-(dimethylamino)-1ethyl-2-methylpropyl]phenol

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780028472.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07787803

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2656696

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007787803

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097000899

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2009521242

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12374894

Country of ref document: US

Ref document number: MX/A/2009/000911

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007278224

Country of ref document: AU

Ref document number: 719/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200970147

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007278224

Country of ref document: AU

Date of ref document: 20070723

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0714671

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090123